AZTA insider buying & filings

← All candidates

AZTAAzenta, Inc.

NasdaqGS · Healthcare · $1.46B

$33.24

-1.16% · Sep 18

Two insider buys in the last year — $171.9K in all.
Nothing in the last fortnight.

Last Form 4 Sep 16 · scanned 40s ago

Price · 1Y · daily● 2 buys◆ 8 8-K

▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained

AI brief · from the filings on this pagePro

The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.

▸ Included with Pro →

Market cap

$1.46B

Float

38.9M

89% public

Short % float

Pro

Price / profit

—

not yet profitable

Price / future profit

56.6

Price / sales

2.4

The buyers

▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions

Director

Cornog William L

Bought $163.8K on May 18 — 10,000 sh @ $16.38, held indirect, 51% of their stake.

0 of 1 position beat the S&P

median +0.7% vs S&P +10.1% same spans · 3 buy-days · 1 positions still open

EVP, CFO and Treasurer

Lin Lawrence Y.

Bought $69.9K on Aug 11 — 2,500 sh @ $27.96, held direct, 5.4% of their stake.

1 of 1 position beat the S&P

median +34.1% vs S&P +9.4% same spans

SVP, Gen Counsel & Secretary

Starr Ephraim

Bought $8.1K on Jul 31 — 335 sh @ $24.17, held direct, 0.5% of their stake.

No completed positions to measure

no positions we can measure against the market — the record starts here

The record

newest first

DateTypeInsiderOf stakeShares @ priceValue

Sep 16GRANTMadaus Martin DInterim CEOdirect36,653 sh—

Sep 16GRANTMartin William E. IIIPresident Multiomicsdirect15,272 sh—

Sep 16GRANTPirogova OlgaSVP and CHROdirect15,272 sh—

Sep 16GRANTLin Lawrence Y.EVP, CFO and Treasurerdirect30,544 sh—

Sep 16GRANTStarr EphraimSVP, Gen Counsel & Secretarydirect15,272 sh—

24 more transactions on Pro →

Context

Wall St

$27.80 avg target

-16.4% vs today · 5 analysts

▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice

Earnings · EPS vs forecast

2 of 4 quarters beat

Q2 '26$0.16 act+$0.06

Q1 '26−$0.04 act−$0.18

Q4 '25$0.09 act−$0.04

Q3 '25$0.21 act+$0.01

Coverage

Winners And Losers Of Q1: Azenta (NASDAQ:AZTA) Vs The Rest Of The Drug Development Inputs & Services StocksStockStory · 05-21 Azenta’s Q1 Earnings Call: Our Top 5 Analyst QuestionsStockStory · 05-16 Azenta, Inc. Q2 2026 Earnings Call SummaryMoby · 05-06 Azenta Q2 Earnings Call HighlightsMarketBeat · 05-06

The file stays open

32 filings on record.
The next one will be too.

All candidates

▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice

Cornog William L

Lin Lawrence Y.

Starr Ephraim

32 filings on record.The next one will be too.

32 filings on record.
The next one will be too.